The Experts below are selected from a list of 77427 Experts worldwide ranked by ideXlab platform
Raquel Abad - One of the best experts on this subject based on the ideXlab platform.
-
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB Strain coverage worldwide.
Vaccine, 2019Co-Authors: Alessandro Muzzi, Raquel Abad, Maurizio Comanducci, Alessandro Brozzi, Laura Serino, Margherita Bodini, Dominique Caugant, Ana Paula Lemos, Maria Cecilia Gorla, Pavla KřížováAbstract:BACKGROUND: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B Strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting Strain coverage by the 4CMenB vaccine. METHODS: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. RESULTS: Overall, 81% of the Strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales Strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS Predicted Strain coverage in other countries was 58-88%. CONCLUSIONS: gMATS can replace MATS in predicting 4CMenB Strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
-
Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
PloS one, 2016Co-Authors: Raquel Abad, Stefania Bambini, Maria Stella, Verónica Medina, Giuseppe Boccadifuoco, Maurizio Comanducci, Alessandro Muzzi, Julio A VazquezAbstract:Background A novel meningococcal multicomponent vaccine, 4CMenB (Bexsero®), has been approved in Europe, Canada, Australia and US. The potential impact of 4CMenB on Strain coverage is being estimated by using Meningococcal Antigen Typing System (MATS), an ELISA assay which measures vaccine antigen expression and diversity in each Strain. Here we show the genetic characterization and the 4CMenB potential coverage of Spanish invasive Strains (collected during one epidemiological year) compared to other European countries and discuss the potential reasons for the lower estimate of coverage in Spain.
-
Predicted Strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
The Lancet Infectious Diseases, 2013Co-Authors: Ulrich Vogel, Muhamed-kheir Taha, Julio Vazquez, Jamie Findlow, Heike Claus, Paola Stefanelli, Dominique Caugant, Paula Kriz, Raquel Abad, Stefania BambiniAbstract:BACKGROUND: A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the Strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the Predicted Strain coverage in Europe. METHODS: We assessed invasive MenB Strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain. FINDINGS: 1052 Strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB Strains contained at least one gene encoding a major antigen in the vaccine. MATS Predicted that 78% of all MenB Strains would be killed by postvaccination sera (95% CI 63-90, range of point estimates 73-87% in individual country panels). Half of all Strains and 64% of covered Strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries. INTERPRETATION: MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB Strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.
-
Predicted Strain coverage of a meningococcal multicomponent vaccine 4cmenb in europe a qualitative and quantitative assessment
Lancet Infectious Diseases, 2013Co-Authors: Ulrich Vogel, Muhamed-kheir Taha, Jamie Findlow, Heike Claus, Paola Stefanelli, Dominique Caugant, Paula Kriz, Raquel Abad, Julio A Vazquez, Stefania BambiniAbstract:Summary Background A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the Strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the Predicted Strain coverage in Europe. Methods We assessed invasive MenB Strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain. Findings 1052 Strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB Strains contained at least one gene encoding a major antigen in the vaccine. MATS Predicted that 78% of all MenB Strains would be killed by postvaccination sera (95% CI 63–90, range of point estimates 73–87% in individual country panels). Half of all Strains and 64% of covered Strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries. Interpretation MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB Strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future. Funding Novartis Vaccines and Diagnostics.
Stefania Bambini - One of the best experts on this subject based on the ideXlab platform.
-
Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
PloS one, 2016Co-Authors: Raquel Abad, Stefania Bambini, Maria Stella, Verónica Medina, Giuseppe Boccadifuoco, Maurizio Comanducci, Alessandro Muzzi, Julio A VazquezAbstract:Background A novel meningococcal multicomponent vaccine, 4CMenB (Bexsero®), has been approved in Europe, Canada, Australia and US. The potential impact of 4CMenB on Strain coverage is being estimated by using Meningococcal Antigen Typing System (MATS), an ELISA assay which measures vaccine antigen expression and diversity in each Strain. Here we show the genetic characterization and the 4CMenB potential coverage of Spanish invasive Strains (collected during one epidemiological year) compared to other European countries and discuss the potential reasons for the lower estimate of coverage in Spain.
-
Predicted Strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
The Lancet Infectious Diseases, 2013Co-Authors: Ulrich Vogel, Muhamed-kheir Taha, Julio Vazquez, Jamie Findlow, Heike Claus, Paola Stefanelli, Dominique Caugant, Paula Kriz, Raquel Abad, Stefania BambiniAbstract:BACKGROUND: A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the Strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the Predicted Strain coverage in Europe. METHODS: We assessed invasive MenB Strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain. FINDINGS: 1052 Strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB Strains contained at least one gene encoding a major antigen in the vaccine. MATS Predicted that 78% of all MenB Strains would be killed by postvaccination sera (95% CI 63-90, range of point estimates 73-87% in individual country panels). Half of all Strains and 64% of covered Strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries. INTERPRETATION: MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB Strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future.
-
Predicted Strain coverage of a meningococcal multicomponent vaccine 4cmenb in europe a qualitative and quantitative assessment
Lancet Infectious Diseases, 2013Co-Authors: Ulrich Vogel, Muhamed-kheir Taha, Jamie Findlow, Heike Claus, Paola Stefanelli, Dominique Caugant, Paula Kriz, Raquel Abad, Julio A Vazquez, Stefania BambiniAbstract:Summary Background A novel multicomponent vaccine against meningococcal capsular group B (MenB) disease contains four major components: factor-H-binding protein, neisserial heparin binding antigen, neisserial adhesin A, and outer-membrane vesicles derived from the Strain NZ98/254. Because the public health effect of the vaccine, 4CMenB (Novartis Vaccines and Diagnostics, Siena, Italy), is unclear, we assessed the Predicted Strain coverage in Europe. Methods We assessed invasive MenB Strains isolated mainly in the most recent full epidemiological year in England and Wales, France, Germany, Italy, and Norway. Meningococcal antigen typing system (MATS) results were linked to multilocus sequence typing and antigen sequence data. To investigate whether generalisation of coverage applied to the rest of Europe, we also assessed isolates from the Czech Republic and Spain. Findings 1052 Strains collected from July, 2007, to June, 2008, were assessed from England and Wales, France, Germany, Italy, and Norway. All MenB Strains contained at least one gene encoding a major antigen in the vaccine. MATS Predicted that 78% of all MenB Strains would be killed by postvaccination sera (95% CI 63–90, range of point estimates 73–87% in individual country panels). Half of all Strains and 64% of covered Strains could be targeted by bactericidal antibodies against more than one vaccine antigen. Results for the 108 isolates from the Czech Republic and 300 from Spain were consistent with those for the other countries. Interpretation MATS analysis showed that a multicomponent vaccine could protect against a substantial proportion of invasive MenB Strains isolated in Europe. Monitoring of antigen expression, however, will be needed in the future. Funding Novartis Vaccines and Diagnostics.
Alessandro Muzzi - One of the best experts on this subject based on the ideXlab platform.
-
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB Strain coverage worldwide.
Vaccine, 2019Co-Authors: Alessandro Muzzi, Raquel Abad, Maurizio Comanducci, Alessandro Brozzi, Laura Serino, Margherita Bodini, Dominique Caugant, Ana Paula Lemos, Maria Cecilia Gorla, Pavla KřížováAbstract:BACKGROUND: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B Strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting Strain coverage by the 4CMenB vaccine. METHODS: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. RESULTS: Overall, 81% of the Strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales Strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS Predicted Strain coverage in other countries was 58-88%. CONCLUSIONS: gMATS can replace MATS in predicting 4CMenB Strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
-
Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries.
PloS one, 2016Co-Authors: Raquel Abad, Stefania Bambini, Maria Stella, Verónica Medina, Giuseppe Boccadifuoco, Maurizio Comanducci, Alessandro Muzzi, Julio A VazquezAbstract:Background A novel meningococcal multicomponent vaccine, 4CMenB (Bexsero®), has been approved in Europe, Canada, Australia and US. The potential impact of 4CMenB on Strain coverage is being estimated by using Meningococcal Antigen Typing System (MATS), an ELISA assay which measures vaccine antigen expression and diversity in each Strain. Here we show the genetic characterization and the 4CMenB potential coverage of Spanish invasive Strains (collected during one epidemiological year) compared to other European countries and discuss the potential reasons for the lower estimate of coverage in Spain.
Christoph Nohe - One of the best experts on this subject based on the ideXlab platform.
-
The chicken or the egg? A meta-analysis of panel studies of the relationship between work-family conflict and Strain.
The Journal of applied psychology, 2014Co-Authors: Christoph Nohe, Laurenz L. Meier, Karlheinz Sonntag, Alexandra MichelAbstract:Does work-family conflict predict Strain, does Strain predict work-family conflict, or are they reciprocally related? To answer these questions, we used meta-analytic path analyses on 33 studies that had repeatedly measured work interference with family (WIF) or family interference with work (FIW) and Strain. Additionally, this study sheds light on whether relationships between WIF/FIW and work-specific Strain support the popular cross-domain perspective or the less popular matching perspective. Results showed reciprocal effects; that is, that WIF Predicted Strain (β = .08) and Strain Predicted WIF (β = .08). Similarly, FIW and Strain were reciprocally related, such that FIW Predicted Strain (β = .03) and Strain Predicted FIW (β = .05). These findings held for both men and women and for different time lags between the 2 measurement waves. WIF had a stronger effect on work-specific Strain than did FIW, supporting the matching hypothesis rather than the cross-domain perspective.
-
Consequences of Work–Family Conflict
2014Co-Authors: Christoph NoheAbstract:Most employees are challenged to combine work and family roles. Although both roles can provide self-esteem, self-fulfillment, and happiness, they can also interfere with each other making it more difficult to fulfill work and family demands. Work–family conflict is the construct that captures interference between work and family roles. High work–family conflict has been associated with potential consequences such as low health, high turnover intentions, and low job performance. My main aim in this dissertation is to extend research on work–family conflict and potential consequences. To this end, I conducted three empirical studies. Study 1 examined the relationship between work–family conflict and Strain, an umbrella term for constructs such as exhaustion, depression, and somatic symptoms. Specifically, my coauthors and I tried to work toward resolving two debates. The first debate is about the direction of relationships between work–family conflict and Strain. We examined whether work–family conflict predicts Strain, whether Strain predicts work–family conflict, or whether work–family conflict and Strain reciprocally predict each other. The second debate is about the pattern of relationships between work–family conflict and domain-specific outcomes. The currently dominant cross-domain perspective suggests that family-to-work conflict (FWC) is mainly related to work-related Strain. The less-popular matching perspective, however, suggests that work-to-family conflict (WFC) is mainly related to work-related Strain. To address those two debates, we applied meta-analytic path analysis to 33 panel studies (total N = 13,029) that had repeatedly measured work–family conflict and Strain. For the direction of relationship, results showed reciprocal relationships for both forms of work–family conflict and Strain. More specifically, WFC Predicted Strain (β = .08) and Strain Predicted WFC (β = .08). Similarly, FWC Predicted Strain (β = .03) and Strain Predicted FWC (β = .05). These findings held for both men and women and for different time lags between the two measurement waves. For the debate on matching versus cross-domain relationships, results showed that WFC had a stronger relationship with work-specific Strain than did FWC, supporting the matching hypothesis. Study 2 focused on work–family conflict and turnover intentions. More specifically, it compared two theoretical perspectives that make competing predictions about the relationships between work–family conflict and domain-specific outcomes. The cross-domain perspective predicts that FWC should be more important than WFC in predicting increases in turnover intentions. The matching perspective, however, predicts that WFC should be more important than FWC in predicting increased turnover intentions. We expanded the debate about matching versus cross-domain relationships by testing whether work-family specific social support should stem from the same domain as the conflict as the matching principle would indicate or from the other domain as the cross-domain perspective would indicate. Additionally, we hypothesized that changes in WFC and FWC predict changes in turnover intentions and tested reciprocal relationships between WFC/FWC and turnover intentions. With a time-lag of five months, 665 employees from a large company filled out surveys at two time points. Results revealed that (increases in) WFC Predicted increased turnover intentions, whereas (increases in) FWC did not. Work-family specific support from the leader buffered the relationship between WFC and increased turnover intentions, but work-family specific support from family and friends did not. Furthermore, results revealed reverse relationships such that turnover intentions Predicted increased WFC and FWC. Taken together, the study results supported the matching principle rather than the cross-domain perspective. The reverse relationships found between work–family conflict and turnover intentions challenge the common view that work–family conflict antecedes turnover intentions unidirectionally. Study 3 examined the cross-domain relationship between work–family conflict and job performance. Overall, Study 3 was intended to better understand work–family conflict as a dynamic construct that changes over short periods, such as from day-to-day. Specifically, we used a within-person daily research paradigm to examine the relationship between daily FWC and daily job performance. On the basis of theory on dynamic behavior, we hypothesized that daily FWC impairs daily job performance through the mechanism of daily concentration. Additionally, we Predicted that psychological detachment from work during time off (i.e., mentally switching off) buffers the negative relationship between daily FWC and daily job performance. Over one workweek, 95 employees from a large German company completed two surveys each day. Multilevel modeling results showed that daily FWC was negatively associated with daily job performance and that daily concentration mediated this relationship. Furthermore, general psychological detachment, but not daily psychological detachment, buffered the negative relationship between daily FWC and daily job performance. The findings of Study 3 advance our understanding of dynamic short-term processes at the intersection of work and family by demonstrating that short-term changes in FWC go along with fluctuations in job performance. This dissertation offers several practical implications. For example, Study 2 shows that work-family specific leader support buffers the relationship between high WFC and high turnover intentions. Study 3 shows that psychological detachment from work during time off buffers the relationship between high FWC and low job performance. Thus, organizations should foster leader support and encourage their employees to psychologically detach from work during time off to buffer the relationship between work–family conflict and relevant business outcomes. In sum, this dissertation contributes to research on work–family conflict and its potential consequences by addressing ongoing debates and gaps in the literature.
Pavla Křížová - One of the best experts on this subject based on the ideXlab platform.
-
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB Strain coverage worldwide.
Vaccine, 2019Co-Authors: Alessandro Muzzi, Raquel Abad, Maurizio Comanducci, Alessandro Brozzi, Laura Serino, Margherita Bodini, Dominique Caugant, Ana Paula Lemos, Maria Cecilia Gorla, Pavla KřížováAbstract:BACKGROUND: The Meningococcal Antigen Typing System (MATS) was developed to identify meningococcus group B Strains with a high likelihood of being covered by the 4CMenB vaccine, but is limited by the requirement for viable isolates from culture-confirmed cases. We examined if antigen genotyping could complement MATS in predicting Strain coverage by the 4CMenB vaccine. METHODS: From a panel of 3912 MATS-typed invasive meningococcal disease isolates collected in England and Wales in 2007-2008, 2014-2015 and 2015-2016, and in 16 other countries in 2000-2015, 3481 isolates were also characterized by antigen genotyping. Individual associations between antigen genotypes and MATS coverage for each 4CMenB component were used to define a genetic MATS (gMATS). gMATS estimates were compared with England and Wales human complement serum bactericidal assay (hSBA) data and vaccine effectiveness (VE) data from England. RESULTS: Overall, 81% of the Strain panel had genetically predictable MATS coverage, with 92% accuracy and highly concordant results across national panels (Lin's accuracy coefficient, 0.98; root-mean-square deviation, 6%). England and Wales Strain coverage estimates were 72-73% by genotyping (66-73% by MATS), underestimating hSBA values after four vaccine doses (88%) and VE after two doses (83%). The gMATS Predicted Strain coverage in other countries was 58-88%. CONCLUSIONS: gMATS can replace MATS in predicting 4CMenB Strain coverage in four out of five cases, without requiring a cultivable isolate, and is open to further improvement. Both methods underestimated VE in England. Strain coverage predictions in other countries matched or exceeded England and Wales estimates.
-
Predicted Strain coverage of a new protein-based meningococcal vaccine in the Czech Republic
Epidemiologie mikrobiologie imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne, 2014Co-Authors: Pavla Křížová, Martin Musilek, Zuzana Vacková, Kozáková J, Claus H, Vogel U, Medini DAbstract:BACKGROUND Recent data indicate that Neisseria meningitidis B Strains cause about 70% of invasive meningococcal disease (IMD) cases in Europe and the availability of a vaccine effective against N. meningitidis B is desirable. A new protein-based MenB vaccine was licensed for use in Europe in January 2013. Meningococcal antigen typing system (MATS) was developed to predict Strain coverage of this vaccine. Reports have recently been published for a European consortium, including aggregated data for the Czech Republic. The aim of this paper is to provide a detailed breakdown of MATS results for the Czech N. meningitidis B isolates. MATERIALS AND METHODS One hundred and eight N. meningitidis B isolates from IMD collected in the Czech Republic during 2007-2010 were selected. MATS analysis was done according to the method previously published. RESULTS Based on MATS analysis, the overall estimate of Strain coverage of the new MenB vaccine for a panel of 108 Czech N. meningitidis B Strains is 74% (95% CI: 59-87%). Thirty-nine Strains (36%) are Predicted to be covered by a single antigen and 41 Strains (38%) by more than one antigen. For 28 Strains (26%), no antigen coverage was found. CONCLUSIONS MATS analysis showed that the new protein-based MenB vaccine could protect against a substantial proportion of IMD caused by N. meningitidis B in the Czech Republic. Continued detailed surveillance of IMD will be essential if the MenB vaccine is introduced to the country.